Moneycontrol
SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Cadila Healthcare

Cadila Healthcare

BSE: 532321|NSE: CADILAHC|ISIN: INE010B01027|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Jun 23, 16:00
522.90
-3.15 (-0.6%)
VOLUME 110,533
LIVE
NSE
Jun 23, 15:49
525.60
0.3 (0.06%)
VOLUME 930,513
News on Cadila Healthcare
Select Year: 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Zydus Cadila Ahmedabad plant gets EIR from USFDA

3.57 pm | 21 Jun 2017 |  Source: PTI

The manufacturing plant had completed the US Food and Drug Administration (USFDA) audit from February 6-15, 2017 with zero Form 483 observations, Zydu...

Cadila Health rebounds on establishment inspection report for Moraiya Unit

12.22 pm | 21 Jun 2017 |  Source: Moneycontrol.com

Zydus Cadila's formulations manufacturing facility at Moraiya has received an establishment inspection report from the USFDA....

Zydus receives EIR report for Moraiya manufacturing facility

11.37 am | 21 Jun 2017 |  Source: Moneycontrol.com

Zydus Cadila’s formulations manufacturing facility at Moraiya, Ahmedabad has received an Establishment Inspection Report from the USFDA signifying t...

Cadila Health's board meeting on June 26, 2017

10.20 am | 21 Jun 2017 |  Source: Moneycontrol.com

A meeting of the Board of Directors is scheduled to be held on Monday, June 26, 2017, to raise funds by issue of Equity Shares / Convertible Bonds / D...

Zydus receives final approval from USFDA for Diflunisal tablets

12.17 pm | 20 Jun 2017 |  Source: Moneycontrol.com

Zydus Cadila has received the final approval from the USFDA to market Diflunisal tablets in the strength of 500 mg....

Zydus Cadila gets USFDA nod to market migraine drug

4.38 pm | 19 Jun 2017 |  Source: PTI

"Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Eletriptan Hydrobromide tablets, 2...

Cadila Health gains 2% on USFDA nod for anti migraine drug, Morgan Stanley overweight call

10.53 am | 19 Jun 2017 |  Source: Moneycontrol.com

Morgan Stanley said with the Moraiya resolution past, it expects the new product approval cycle for the US market to intensify....

Zydus receives final approval from USFDA for Eletriptan Hydrobromide tablets

10.20 am | 19 Jun 2017 |  Source: Moneycontrol.com

Zydus Cadila has received the final approval from the USFDA to market Eletriptan hydrochloride tablets, 20 mg (base) and 40 mg (base)....

Cadila Healthcare gains 2% on USFDA approval for anti-retroviral drug

12.21 pm | 15 Jun 2017 |  Source: Moneycontrol.com

Cadila group, so far, has received approvals for four drugs that have been filed from its Moraiya facility....

Zydus receives final approval from USFDA for Acyclovir for injection USP

10.10 am | 15 Jun 2017 |  Source: Moneycontrol.com

Zydus Cadila has received final approval from the USFDA to market Acyclovir for injection USP in strengths of 500mg/vial and 1000 mg/vial....

Cadila Healthcare at 1-year high on USFDA approval to market Nystatin Topical Powder

10.59 am | 12 Jun 2017 |  Source: Moneycontrol.com

Nystatin Topical Powder is an antifungal antibiotic used to treat skin infections caused by yeast....

Pharma weekly wrap: US FDA approvals, GST rollout keep sector buzzing

12.46 pm | 10 Jun 2017

After last week's resurgence - this week saw pharma stocks extending their gains. Some big US approvals, domestic market numbers, impending drug s...

Indian drug market growth slows at 7.3% in May

10.04 pm | 08 Jun 2017 |  Source: Moneycontrol.com

The Indian pharmaceutical market grew at much slower pace in May due to declining sales of anti-infective medicines and sluggish growth in dermatology...

Hold Cadila Healthcare; target of Rs 420: Axis Direct

4.26 pm | 07 Jun 2017 |  Source: Moneycontrol.com

Axis Direct recommended hold rating on Cadila Healthcare with a target price of Rs 420 in its research report dated June 06, 2017....

Top buzzing midcap stocks to trade on June 7 

1.22 pm | 07 Jun 2017 |  Source: CNBC-TV18

Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today -- Cadila Health, Edelweiss, IIFL, Vivimed Labs, Future Ent...

Above Rs 340, Adani Ports may hit Rs 370, stay with housing finance: Gujral 

12.21 pm | 07 Jun 2017 |  Source: CNBC-TV18

Above Rs 340, Adani Ports may hit Rs 370, stay with housing finance, says Ashwani Gujral of ashwanigujral.com....

Zydus Cadila gets USFDA nod for mesalamine tablets

11.33 am | 07 Jun 2017 |  Source: PTI

The USFDA has given its final approval to market mesalamine delayed-release tablets USP 1.2 g in the US market. Zydus Cadila was the first to file an ...

Zydus gets US FDA nod for Mesalamine; Cadila Healthcare at record high, up 7% 

10.01 am | 07 Jun 2017 |  Source: Moneycontrol.com

Zydus Cadila was the first to file an abbreviated new drug application for a generic version of Lialda, the company said....

Cadila Healthcare up 4% on establishment inspection report from USFDA for Baddi

11.44 am | 06 Jun 2017 |  Source: Moneycontrol.com

Cadila Healthcare received establishment inspection report (EIR) from the US health regulator for Baddi unit....

Cadila Healthcare gets EIR from USFDA for Baddi facility

7.47 pm | 05 Jun 2017 |  Source: PTI

Drug firm Cadila Healthcare has received Establishment Inspection Report (EIR) from the US health regulator for its Baddi facility in Himachal Pradesh...

1 2 3 4 5
Quick Links for Cadila Healthcare
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.